Fig. 6

Combining tigecycline use with autophagy inhibition shows synergetic cytotoxicity against CML cells. (a) Protein level of LC3B in CML cells that were treated with tigecycline and/or chloroquine (CQ). (b) Assay of apoptosis of CMLcells exposed to tigecycline, CQ, 3-methyladenine(3-MA), or their combination treatment. (c) ATG5 protein levels in KBM5 and KBM5-STI cells that were transiently transfected with siATG5 and evaluated by western blotting. (d) LC3B protein levels in CML cells with and without ATG5 knockdown were measured after treatment with tigecycline. (e) Apoptotic assay of CML cells subjected to ATG5 silence after stimulation with tigecycline. *P < 0.05